Origio Sequential Fert
Payments companies reported to CMS as associated with Origio Sequential Fert. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Origio Sequential Fert, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Origio Sequential Fert
These are the largest totals companies reported as associated with Origio Sequential Fert. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Theresa Huszar | Milford, CT | $54,747.73 | |
| James Lin | Irvine, CA | Reproductive Endocrinology | $652.36 |
| Daniel Williams | Sugar Land, TX | Reproductive Endocrinology | $553.30 |
| Michael Scheiber | Cincinnati, OH | Reproductive Endocrinology | $478.22 |
| Susan Nasab | Lutherville, MD | Obstetrics & Gynecology | $336.56 |
| Kenneth Moghadam | Carmel, IN | Reproductive Endocrinology | $232.07 |
| Inderbir Gill | Houston, TX | Reproductive Endocrinology | $232.06 |
| Ghassan Haddad | Houston, TX | Reproductive Endocrinology | $232.06 |
| Christopher Montville | Franklin, TN | Reproductive Endocrinology | $208.40 |
| Peter Klatsky | San Francisco, CA | Reproductive Endocrinology | $175.47 |
Prescribed Origio Sequential Fert?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.